Controls severe or incapacitating allergic conditions. ANDA 76913, held by Pharm Assoc. Prednisolone Sodium Phosphate.
As of Nov 16, 2026, ANDA 76913 (Prednisolone Sodium Phosphate), held by Pharm Assoc, was first approved by FDA on Apr 25, 2005, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Prednisolone Sodium Phosphate Oral Solution (15 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 25, 2005 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Prednisolone Sodium PhosphateEQ 15MG BASE/5ML · solution;oral | Prednisolone Sodium Phosphate | Rx |
| Apr 18, 2025 | Supplement 16Manufacturing | Approved | None posted |
| Jun 5, 2024 | Supplement 14Labeling · Standard review | Approved | None posted |
| Apr 16, 2010 | Supplement 6Labeling | Approved | None posted |
| Jun 2, 2009 | Supplement 4Labeling | Approved | None posted |
| Oct 5, 2007 | Supplement 2Manufacturing | Approved | None posted |
| Apr 25, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters